293 related articles for article (PubMed ID: 2494006)
1. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis.
Jang IK; Gold HK; Ziskind AA; Fallon JT; Holt RE; Leinbach RC; May JW; Collen D
Circulation; 1989 Apr; 79(4):920-8. PubMed ID: 2494006
[TBL] [Abstract][Full Text] [Related]
2. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
Yasuda T; Gold HK; Leinbach RC; Saito T; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
J Am Coll Cardiol; 1990 Dec; 16(7):1728-35. PubMed ID: 2123910
[TBL] [Abstract][Full Text] [Related]
3. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
Gold HK; Yasuda T; Jang IK; Guerrero JL; Fallon JT; Leinbach RC; Collen D
Circulation; 1991 Jun; 83(6 Suppl):IV26-40. PubMed ID: 2040069
[TBL] [Abstract][Full Text] [Related]
4. G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs.
Lu HR; Gold HK; Wu Z; Yasuda T; Pauwels P; Rapold HJ; Napier M; Bunting S; Collen D
Thromb Haemost; 1992 Jun; 67(6):686-91. PubMed ID: 1509410
[TBL] [Abstract][Full Text] [Related]
5. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
[TBL] [Abstract][Full Text] [Related]
6. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
Yasuda T; Gold HK; Fallon JT; Leinbach RC; Garabedian HD; Guerrero JL; Collen D
J Am Coll Cardiol; 1989 May; 13(6):1409-14. PubMed ID: 2495318
[TBL] [Abstract][Full Text] [Related]
7. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
Przyklenk K; Kloner RA
Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
[TBL] [Abstract][Full Text] [Related]
8. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
Golino P; Ashton JH; Glas-Greenwalt P; McNatt J; Buja LM; Willerson JT
Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog.
Kopia GA; Kopaciewicz LJ; Fong KL; Crysler CS; Boyle K; Ruffolo RR
J Cardiovasc Pharmacol; 1988 Sep; 12(3):308-16. PubMed ID: 2464103
[TBL] [Abstract][Full Text] [Related]
11. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
12. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
[TBL] [Abstract][Full Text] [Related]
13. Retrograde coronary venous administration of recombinant tissue-type plasminogen activator: a unique and effective approach to coronary artery thrombolysis.
Miyazaki A; Tadokoro H; Drury JK; Rydén L; Haendchen RV; Corday E
J Am Coll Cardiol; 1991 Aug; 18(2):613-20. PubMed ID: 1906906
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
Mickelson JK; Simpson PJ; Cronin M; Homeister JW; Laywell E; Kitzen J; Lucchesi BR
Circulation; 1990 Feb; 81(2):617-27. PubMed ID: 2105175
[TBL] [Abstract][Full Text] [Related]
16. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
[TBL] [Abstract][Full Text] [Related]
17. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.
Jang IK; Gold HK; Ziskind AA; Leinbach RC; Fallon JT; Collen D
Circulation; 1990 Jan; 81(1):219-25. PubMed ID: 2297828
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of the platelet 5HT2 receptor in the presence of thrombolysis.
Belcher PR; Drake-Holland AJ; Noble MI
Int J Cardiol; 1994 Jan; 43(1):11-20. PubMed ID: 8175214
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
Lynch JJ; Sitko GR; Mellott MJ; Nutt EM; Lehman ED; Friedman PA; Dunwiddie CT; Vlasuk GP
Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
[TBL] [Abstract][Full Text] [Related]
20. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
Van de Werf F; Jang IK; Collen D
J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
